Cerus Corporation (Nasdaq) announced today its participation in the 38th International Congress of the International Society of Blood Transfusion (ISBT) in Barcelona, Spain, from June 23 to June 27. This global event gathers experts and professionals in transfusion medicine.
Key activities include a lunch symposium and various selected abstract presentations focusing on pathogen inactivation technologies.
Highlights of Oral Presentations:
- Thursday, June 27, 2024 – 12:30 p.m. – Cerus Lunch Symposium – Pathogen Inactivation: Further evidence for implementation
- The natural virome and pandemic potential: Disease X
- Comparison of clinical outcomes in cardiac surgery, using INTERCEPT platelets and conventional platelets
- Benefits and challenges of implementing pathogen inactivation methods – the importance of high-quality randomized clinical studies
- Thursday, June 27, 2024 – 11:15 a.m. – Quantifying Residual Red Blood Cells in Platelet and Plasma Components: Flow Cytometry and a Visual Inspection Tool Support Implementation of Pathogen Inactivation
Poster Presentations:
- Various posters from June 24 to June 27, 2024, including studies on cold-storage of Amotosalen-UVA Pathogen-Reduced Buffy-Coat Platelet Concentrates and safety assessments of Amotosalen/UVA Platelets and Plasma.
Cerus will be available at booth #D.18 in the exhibition area.
About Cerus: Cerus Corporation, headquartered in Concord, California, focuses on safeguarding the global blood supply through innovative technologies. Its INTERCEPT Blood System for platelets and plasma is globally recognized for pathogen reduction, holding both CE Mark and FDA approval. The company is also advancing its systems for red blood cells and cryoprecipitation through regulatory processes.
